One less competitor in the oral psoriasis drug market means one more potential suitor for P if result is positive. Here’s the correct link.

https://endpts.com/allergans-639m-vitae-buyou...lete-loss/

Here’s the original deal.

Allergan in $640M Vitae buyout deal as it further expands dermatology pipeline

"Allergan buys into the Fort Washington, PA-based biotech’s dermatology pipeline that includes VTP-43742, a midstage, first-in-class, orally active ROR?t (retinoic acid receptor-related orphan receptor gamma) inhibitor for the potential treatment of psoriasis, as well as other autoimmune disorders."

http://www.fiercebiotech.com/biotech/allergan...y-pipeline

"The compound recently completed a Phase 2 proof-of-concept multiple ascending dose trial in patients with moderate to severe psoriasis."

https://www.allergan.com/news/news/thomson-re...s-adding-i